Understanding RSV

Respiratory Syncytial Virus, or RSV, is a common virus known to cause lower respiratory tract infections, affecting the lungs and breathing passages. It is highly contagious and can lead to severe complications, particularly in older adults with pre-existing conditions such as heart and lung diseases. According to the CDC, RSV is responsible for a significant number of hospitalizations and deaths in the U.S. each year among adults aged 65 and older, so it’s definitely not something to ignore. It's also important to consult with a healthcare professional to assess individual risk factors when considering vaccination.

RSV Season and Contagiousness

RSV season typically occurs in late fall and early winter. During this period, the virus tends to be more active and spreads more easily. Due to its high contagiousness, it's important to take preventive measures to reduce the risk of transmission, especially for vulnerable populations.

Introducing the RSV Vaccine: Arexvy (nirsevimab)

Arexvy marks a significant milestone as the first RSV vaccine approved for use in the United States. Unlike "older" vaccines that stimulate the body to produce its own antibodies, Arexvy is an adjuvanted recombinant subunit vaccine that functions by triggering an immune response against the RSVpreF3 antigen, a crucial protein found on the surface of RSV. This produces antibodies that can effectively combat the virus if the body ever becomes infected by RSV. Administered as a single intramuscular shot, typically in the deltoid muscle of the upper arm, Arexvy offers a promising tool in the fight against RSV.

Who Should Consider Getting the RSV Vaccine

While Arexvy is primarily recommended for those aged 60 and older (once they have talked with their doctor about it), individuals under 60 with specific medical conditions can also consider vaccination. These conditions include lung diseases like COPD and asthma, cardiovascular diseases such as congestive heart failure and coronary artery disease, and moderate to severe immune compromise, among others. Additionally, pregnant individuals who may need vaccination can get the maternal RSV vaccine (ABRYSVO™) during weeks 32 to 36 to protect infants from RSV lower respiratory tract infections.

RSV Vaccine Side Effects

The RSV vaccine does not contain any live virus. Common side effects may include injection site pain, fatigue, muscle pain, headache, and joint stiffness or pain. Less commonly reported but more severe side effects can include anaphylaxis (in case of allergies), fainting, atrial fibrillation, acute disseminated encephalomyelitis (ADEM), and Guillain-Barré syndrome. 

Conclusion

The introduction of the RSV vaccine represents a significant advancement in preventive healthcare, offering a vital tool in combating the potentially severe effects of RSV infections. While the vaccine is primarily recommended for older adults and individuals with specific medical conditions, its availability is a positive step towards safeguarding public health during RSV season. Consulting with a healthcare provider is crucial for making informed decisions about RSV vaccination.

Resources

-https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine

-https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/rsv.html

-https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#addendum-child

-https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm

-https://www.drugs.com/arexvy.html

‍